Medication info
Linadiem Met Extended-Release Tablet 5/1000 mg (Linagliptin, Metformin)

Linadiem Met Extended-Release Tablet 5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Dongwha Pharm Co., Ltd.
Appearance
Pink, biconvex, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202400383 · Approved 2024.02.22 · Insurance code 642707550

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and extended-release metformin hydrochloride 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this 5/1000 mg extended-release tablet once daily. Patients taking this 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate, if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be equivalent to the current doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment As dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically during treatment with this medicine. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A) with creatine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dosage adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45mL/min or estimated glomerular filtration rate (eGFR) decreases to below 45mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Dongwha Pharm Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes

View approved original text

This medication is used in combination with dietary and exercise therapy to improve blood glucose control in patients with type 2 diabetes by administering Linagliptin and Metformin together. It helps manage blood sugar levels more effectively.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and extended-release metformin hydrochloride 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this 5/1000 mg extended-release tablet once daily. Patients taking this 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate, if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be equivalent to the current doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment As dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically during treatment with this medicine. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A) with creatine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dosage adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45mL/min or estimated glomerular filtration rate (eGFR) decreases to below 45mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication helps control blood sugar levels. However, it can rarely cause a dangerous condition known as lactic acidosis, so caution is required. Lactic acidosis occurs when there is an excessive buildup of lactic acid in the body and can be life-threatening if not treated. This medication should not be used in individuals with an allergy to it, type 1 diabetes, severely impaired renal function, or acute infections or serious illnesses. Additionally, it should not be administered to patients with liver dysfunction or those who are alcohol dependent. When using this medication, hypoglycemia may occur, so blood glucose levels should be monitored frequently, especially when taken together with insulin or sulfonylureas. Patients with diminished renal function should have regular kidney function tests, and if kidney function falls below a certain threshold, this medication should not be taken. Caution is also advised for patients with compromised heart function. If iodinated contrast agents are used during radiological examinations, this medication should be discontinued before and after the examinations and renal function should be checked. Patients scheduled for surgery should stop taking this medication 48 hours before the surgery and can resume it once kidney function has been confirmed to have recovered afterward. If sudden abdominal pain, vomiting, severe joint pain, skin rash, or blisters occur during the use of this medication, consult a physician immediately. Long-term use may lead to vitamin B12 deficiency, so regular blood tests to check vitamin B12 levels are advisable. This medication should be swallowed whole without chewing or crushing, although the tablet coating may appear in the stool, which is normal. It is advisable to avoid using this medication during pregnancy and breastfeeding, and consult a physician if planning to become pregnant. Safety in children has not been established, and elderly patients should adjust the dosage considering renal function and have regular kidney function tests. In case of overdose, the medication may not be fully absorbed in the gastrointestinal tract, leading to a risk of lactic acidosis, so immediate medical attention should be sought. This medication should be stored away from moisture and kept out of reach of children; it is not recommended to transfer it to another container.

Side effects

Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reaction, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemic syndrome, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function test, hepatitis, itching, erythema, rash, blistering dermatitis, severe joint pain with disability, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, small intestinal and colonic inflammation, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's disease, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, dizziness, kidney transplant failure, pneumonia, hypercholesterolemia, insufficient control of diabetes, malnutrition, hyponatremia, dizziness, sensory loss, asthenia, epistaxis, oropharyngeal pain, dysphonia, allergic rhinitis, exercise-induced respiratory distress, wet cough, runny nose, lung mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, elevated plasma triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, elevated serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, male pattern baldness, hyperhidrosis, hair loss, dermatitis, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, laceration, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, hearing loss, erectile dysfunction, goiter, altered mental status, nocturia, dermatitis, hypertension, benign prostatic hyperplasia, stomatitis, mediastinitis, vitreous hemorrhage, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air and moisture, so it must be stored in a tightly closed container. The appropriate storage temperature is room temperature between 1 and 30 degrees Celsius, and it is advisable to avoid excessively hot or cold places.

Appearance and packaging

Appearance

Pink, biconvex, oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.